---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-26-000004"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:19:05.226408+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q4 revenue up 11% to $190M; full-year net loss widens to $108M; RaDaR ST MRD launch imminent

## Summary
- Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.
- Q4 net loss decreased 36% to $10M; full-year net loss increased 37% to $108M; Adjusted EBITDA positive $13M (Q4) and $43M (FY).
- Clinical NGS volumes grew 23% in Q4 and 22% for full year, outpacing market growth.
- RaDaR ST MRD assay imminent clinical launch; company addresses $20B+ MRD monitoring market; modest 2026 revenue expected.
- Successfully resolved RaDaR ST patent litigation (no financial details disclosed).

## SEC filing metadata
- accession: 0001077183-26-000004
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000004/0001077183-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000004/neo-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-26-000004
- JSON: https://secwatch.observer/filing/0001077183-26-000004.json
- Plain text: https://secwatch.observer/filing/0001077183-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.